text_1: Pioglitazone use is significantly associated with an increased risk of prostate cancer.
text_2: Results were similar in case-control analyses (pioglitazone use: 19.6% among case patients and 17.5% among controls; adjusted odds ratio, 1.18; 95% CI, 0.78-1.80).